Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in NeoRAS Wild-type mCRC
NCT06440902Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Dec 2023; status: recruiting.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06440902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440902.